Halozyme Projects Zero to Minimal Royalty Impact From Medicare Rule
Halozyme Therapeutics announced on November 6, 2026 that it projects zero to minimal impact on royalty revenue through at least 2035 after analyzing the final Medicare Drug Price Negotiation Program rule issued by the U.S. Centers for Medicare & Medicaid…
Bio-Thera Wins China Approval for Golimumab Biosimilar ASHULI
Bio-Thera Solutions announced on November 6, 2026 that China’s National Medical Products Administration (NMPA) had approved its marketing authorization for BAT2506, a golimumab biosimilar that will be marketed as ASHULI for rheumatoid arthritis and ankylosing spondylitis. The decision adds China…
Lilly and Hims & Hers Formalize Self-Pay Obesity Drug Access
Eli Lilly and Hims & Hers announced an agreement on November 6, 2026 to expand access to Zepbound and Foundayo through the Hims & Hers platform. Eligible patients prescribed either medicine by a licensed provider on the platform will have…
Halozyme Raises 2026 Guidance as Royalty Revenue Jumps 44%
Halozyme Therapeutics reported its third-quarter results on November 5, 2026, posting a 39% year-over-year revenue increase to $493.0 million and raising its full-year 2026 guidance for revenue, royalties, adjusted EBITDA and non-GAAP diluted earnings per share. The results covered the…
Amphastar Q3 Net Income Rises to $37.8 Million as Revenue Grows 8%
Amphastar Pharmaceuticals reported on November 5, 2026 that net revenue for the third quarter ended September 30, 2026 rose 8% year over year to $207.6 million, while GAAP net income increased to $37.8 million from $17.4 million. Diluted earnings were…
Intensity Therapeutics Q3 Loss Widens as Trial Enrollment Resumes
Intensity Therapeutics reported a third-quarter 2026 net loss of $3.54 million on November 5, 2026, compared with $2.67 million in the same quarter of 2025, as new-patient enrollment activities resumed in its Phase 3 soft-tissue sarcoma study. The higher research…
Akeso’s Ivonescimab Wins China Priority Review in Biliary Cancer
Akeso announced on November 4, 2026 that China’s National Medical Products Administration had granted Priority Review to ivonescimab plus chemotherapy for first-line treatment of locally advanced or metastatic biliary tract cancer. The designation is expected to accelerate the subsequent regulatory…
Schrödinger Raises 2026 Outlook as Q3 Revenue Grows 19%
Schrödinger raised its full-year 2026 annual contract value (ACV) and drug-discovery revenue guidance on November 4, 2026, when it reported third-quarter revenue of $64.5 million, up 19% from a year earlier. Under the revised forecast, full-year ACV is $222 million…
Ryvu Reports Early Dapolsertib Data in Phase II Lymphoma Trial
Ryvu Therapeutics and Menarini Group announced on November 4, 2026 the first clinical data from the Phase II JASPIS-01 study of dapolsertib monotherapy in relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: four of the 15 patients treated by the data…
Amgen Raises 2026 Outlook as Q3 Revenue Grows 8% to $10.4 Billion
Amgen announced third-quarter 2026 results on November 3, 2026, reporting an 8% year-over-year increase in total revenue to $10.365 billion and raising its full-year revenue and adjusted earnings per share (EPS) outlook. Product sales also rose 8% to $9.883 billion,…
Lupin Launches Raltegravir With 180-Day Exclusivity Eligibility
Lupin announced on November 3, 2026 that it had launched raltegravir tablets USP 600 mg in the United States following U.S. Food and Drug Administration approval of its Abbreviated New Drug Application. The drugmaker said it is the exclusive first-to-file…
Bayer Raises 2026 Outlook as Pharmaceuticals Drive Q3 Growth
Bayer raised its 2026 adjusted earnings and cash-flow targets on November 3, 2026, after Pharmaceuticals drove third-quarter growth. Group sales reached €10.053 billion, up 4.1% as reported and 1.9% after currency and portfolio adjustments, while EBITDA before special items, which…
Karyopharm Files Chapter 11 and Plans Merger With Ayrmid
Karyopharm Therapeutics announced on November 2, 2026 that it has entered into a Restructuring Support Agreement with its existing lenders and noteholders and other key stakeholders, providing for a merger between Ayrmid Ltd. and a reorganized Karyopharm. To implement the…
InventisBio Nomelcitinib Meets Phase III Endpoints in Plaque Psoriasis
InventisBio Co., Ltd. announced topline results on November 2, 2026, from a registrational Phase III trial of its oral JH2 selective TYK2 inhibitor nomelcitinib (D-2570) in patients with moderate-to-severe plaque psoriasis. The company said the study met both its primary…
Fresenius Signs WuXi Biologics Pact for Up to 37 Biosimilar Candidates
Fresenius SE & Co. KGaA announced on November 2, 2026, that it has entered an exclusive development agreement with WuXi Biologics, a global contract research, development and manufacturing organization, giving Fresenius exclusive access to up to 37 identified biosimilar candidates…
